Market open · Delayed intraday data · 1:08 PM ET
Last update: Nov 9, 2026, 1:02 PM ET

Technology

Snowflake (SNOW) Jumps 16% on a Q2 Beat-and-Raise as a Software Pop Fades

Snowflake jumped as much as 26% intraday to a 52-week high of $384.56, then pared the gain to close up about 16.5% at $356.47, after reporting fiscal second-quarter results the evening before that beat and — the part that moves stocks — raised full-year guidance. Product revenue re-accelerated to about 37% growth ($1.49 billion), adjusted earnings of about $0.62 topped the ~$0.45 expected, and management lifted its full-year product-revenue target to roughly $6.07 billion while widening its margin outlook. The beat-and-raise sparked a sympathy surge across software — Datadog and MongoDB edged higher — on the idea that AI is a tailwind rather than a threat, but that broader enthusiasm largely faded by the close, leaving both peers up only about 2.5% while Snowflake held its gain. The catch is the price: after a ~55% year, Snowflake trades near 15 times forward sales and is still GAAP-unprofitable on heavy stock comp, though it closed somewhat below the average analyst target even after a wave of same-day target increases.

By Roberto LiccardoPublished (ET)8 min readSNOW
An abstract visualization of a large-scale cloud data center with glowing blue server racks and flowing streams of data, representing Snowflake's cloud data platform.

Why Snowflake stock surged — a beat-and-raise to a 52-week high

On Thursday, September 3, 2026, Snowflake (NYSE: SNOW) jumped as much as 26% intraday to a 52-week high of $384.56, then pared the gain to close up about 16.5% at $356.47, from a $305.84 prior close [1]. The catalyst was concrete and freshly dated: after the close the evening before, Snowflake reported fiscal second-quarter results that beat on both revenue and earnings and, crucially, raised full-year guidance [2]. It was the kind of clean beat-and-raise the market had been waiting for from a high-multiple software name — and it sparked a sympathy surge across enterprise-software stocks, though much of that broader enthusiasm faded by the close [5].

Inside the quarter: re-accelerating growth

The headline was growth that sped up rather than slowed. Product revenue — the core measure of Snowflake's consumption business — rose about 37% year over year to roughly $1.49 billion, an acceleration and the company's second consecutive quarter of record sequential dollar growth; total revenue was about $1.55 billion, up ~35% [2]. Adjusted (non-GAAP) earnings came in near $0.62 a share, well ahead of the roughly $0.45 analysts expected [2]. Management then did the thing that moves stocks most: it raised the full-year product-revenue outlook to about $6.07 billion (from roughly $5.84 billion in May) and lifted its adjusted operating-margin target to about 14.5% [2]. Profitability is improving alongside growth — non-GAAP operating margin expanded more than 400 basis points to about 15% — and the AI story is showing tangible adoption, with Snowflake's AI coding agent reaching roughly 9,100 accounts, up about 2,000 in the quarter [2]. Growth, margins and AI traction all moving the right way at once is what sent the shares soaring.

Two-panel chart titled 'Snowflake (SNOW): a beat-and-raise, while the sympathy pop faded.' The left panel shows September 3 closing stock moves: Snowflake up about 16.5%, Datadog (DDOG) up about 2.6%, MongoDB (MDB) up about 2.4%, and the software ETF (IGV) up about 3.4% — Snowflake held its gain on its own results while the sympathy lift in peers was small and largely faded by the close. The right panel shows Snowflake's share price — a 52-week low of $118, a prior close of about $306, and a September 3 close of about $356 (after an intraday high of $385) — noting the roughly 16.5% earnings-day gain. A stat strip shows the 16.5% closing move, product revenue up 37%, the raised full-year product-revenue guidance of about $6.07 billion, four same-day analyst target increases (plus a William Blair Buy reiteration), and a $124 billion market value.
Snowflake jumped as much as ~26% intraday but closed up about 16.5% — holding its gain on its own beat-and-raise, while a modest sympathy lift in peers largely faded by the close: Datadog and MongoDB rose only modestly and finished up about 2.5%, with the software ETF (IGV) up about 3.4%. The initial enthusiasm reflected easing fears that AI would disrupt software. Sources: StockAnalysis; company release; market data, Sep 2026.

Priced for a lot

The bull case still has to contend with the price. Even before Thursday, Snowflake had climbed about 55% over the past year, and the earnings-day gain left it trading at roughly 15 times forward sales — a demanding multiple, and one that assumes years of 25%-plus growth [3]. The company is still unprofitable on a GAAP basis (a trailing net loss of about $1.1 billion, weighed down by heavy stock-based compensation), though that understates the cash economics: Snowflake generates roughly $1.2 billion of free cash flow a year at a 67% gross margin [3]. Even after the jump, the shares closed somewhat below the average analyst price target near $395 (captured that session, and climbing as firms raised targets), so the Street still sees room — the debate is whether re-accelerating growth and expanding margins justify paying such a premium multiple.

Why it matters

Snowflake's jump is about more than one quarter. For two years, the fear hanging over software has been that generative AI would disrupt incumbent platforms — that AI could hollow out the value of databases, analytics and SaaS tools. September 3 was, for a session, the market voting the other way: Snowflake's beat-and-raise sparked a sympathy surge across data-software names — Datadog and MongoDB edged higher — on the idea that AI is a tailwind, not a threat, since enterprises adopting AI need more data infrastructure, more observability and more managed databases, not less. But that broader enthusiasm largely faded by the close; it was Snowflake's own numbers that held. Snowflake, whose whole pitch is to be the place enterprise data lives and where AI models are fed, is a natural bellwether for the AI-tailwind thesis — and holding a ~16.5% gain while peers managed only small gains was the clearest sign that its blowout quarter, more than the sector narrative, was the durable signal.

Snowflake held; the sympathy pop faded, in one cross-section

The same-day tape shows Snowflake held its earnings gain while the sympathy surge in its peers largely faded by the close [5]:

Name (ticker)Sept 3, 2026Read-through
SNOW — Snowflake≈+16.5% (close)Fiscal-Q2 beat-and-raise; product revenue +37%, guidance lifted — held its gain [1][2]
DDOG — Datadog≈+2.6% (close)A modest sympathy gain 14 rose only single digits intraday, gave part back [5]
MDB — MongoDB≈+2.4% (close)Revenue up ~30% to ~$772M, but its intraday pop also faded [5]
IGV — Software ETF≈+3.4%The broad software group finished up modestly [5]

Snowflake closing up ~16.5% on its own beat-and-raise while the peers that rose in sympathy finished up only ~2.5% is the signal: the durable move was company-specific, and the broader AI-software enthusiasm proved thin outside the name that actually delivered [5].

What the Street thinks

The sell side rushed to raise targets. The consensus is a Strong Buy, and even after the pop the average 12-month target of about $395 — captured that session, and rising as firms lifted estimates — sat about ~11% above the closing price, in a wide range from a low near $110 to a high of $525 [6]. On the morning after the print, a wave of firms lifted their targets: Scotiabank's Patrick Colville to $440 (from $320), Cantor Fitzgerald's Thomas Blakey to $430 (from $405), Raymond James's Adam Tindle to $425 (from $275), and Deutsche Bank's Brad Zelnick to $400 (from $350), while William Blair's Jason Ader reiterated a Buy [6]. That the average target still sits just above the price, even after those increases, is the tension in a single number: analysts love the story but the stock has already moved a long way to meet them.

What to watch

  • Consumption trends. Whether product-revenue growth holds in the mid-30s%, the clearest signal that AI workloads are driving usage [2].
  • Margins and stock comp. Continued non-GAAP margin expansion, and whether GAAP losses narrow as stock-based compensation moderates [3].
  • AI monetization. Adoption of Snowflake's AI features and agents, the proof that the "AI tailwind" translates into paid consumption [2].
  • Valuation versus targets. Whether growth can carry a stock that already trades near consensus and at ~16x sales. Moves are tracked on the SNOW stock page [1].

Illustrative valuation sensitivity

The scenarios below are anchored to Snowflake's growth and margin trajectory and to the analyst target distribution (low near $110, average ~$395, high $525) [6], turning on how durably the AI-data thesis drives consumption. They are a descriptive, author-weighted exercise — not a forecast, target, recommendation, or intrinsic fair-value calculation — with subjective weights that sum to 100%.

ScenarioIllustrative priceWeightKey drivers
Upside~$49030%Growth holds above 30% as AI workloads compound, margins keep expanding, and the multiple stays rich as the stock re-rates toward the bullish targets [6].
Middle~$40040%Strong but decelerating growth carries the stock toward the average target, with the multiple roughly stable as it consolidates the earnings gains [6].
Downside~$30030%The AI-software enthusiasm cools or growth slows, and a ~16x forward-sales multiple compresses back toward pre-earnings levels [3].

Weighting those (0.30 × $490 + 0.40 × $400 + 0.30 × $300) gives an author-weighted reference value near $397, above Thursday's ~$356 close and roughly in line with the ~$395 consensus target [1][6] — reflecting a high-growth franchise the market has just re-rated on a strong quarter, with the debate now about how much of the AI-data upside is already priced. This is a Street-target-and-growth-based scenario exercise and descriptive analysis of a news move, not investment advice.

SNOW data snapshot — September 3, 2026

FigureValueAs-of / source
Close$356.47, up ~16.5% on the day (after an intraday high of $384.56, a 52-week high) — settled closeThu, Sep 3, 2026 — StockAnalysis [1]
Prior close / open / range$305.84 prior close; gapped open $379.23; day range $370.30–$384.00Sep 3, 2026 [1]
52-week range / trend$118.30–$384.00; up ~55% over the past year; well above its ~$296 50-day and ~$219 200-day averages; RSI ≈71 (overbought)As of Sep 3 [3]
Market cap / EV≈$124B at the close (346.6M shares); enterprise value ≈$124B; beta ≈1.33Sep 3 — StockAnalysis [3]
Valuation≈23× trailing sales (≈15× forward) at the close; GAAP-unprofitable (trailing net loss ≈$1.1B on heavy stock comp), but ~$1.2B free cash flow; gross margin ≈67%Sep 3 — StockAnalysis [3]
Q2 results (reported Sep 2, after close)Product revenue ≈$1.49B (+37% YoY); total revenue ≈$1.55B (+35%); adjusted EPS ≈$0.62 vs ~$0.45 est; non-GAAP operating margin ≈15% (+400bps YoY)Fiscal Q2 FY2027 — company [2]
GuidanceRaised full-year product-revenue outlook to ≈$6.07B (from ~$5.84B in May); Q3 product-revenue guide ≈$1.59B; FY adjusted operating margin ≈14.5%Sep 2, 2026 — company [2]
Same-day peers (close)DDOG +~2.6%, MDB +~2.4% (single-digit intraday highs, partly faded); IGV software ETF +~3.4% — a modest sympathy lift; SNOW vastly outperformedSep 3 [5]
Analyst viewConsensus Strong Buy (35 Strong Buy / 10 Buy / 7 Hold of 52), avg target ≈$395 — ~6% above the price, range ~$110–$525; same-day target raises from Scotiabank ($440), Cantor ($430), Raymond James ($425), Deutsche Bank ($400)Sep 2026 — StockAnalysis / analyst notes [6]

Snowflake (SNOW) stock FAQ

Why did Snowflake (SNOW) stock surge on September 3, 2026?

Snowflake jumped as much as 26% intraday to a 52-week high of $384.56, then pared the gain to close up about 16.5% at $356.47, after reporting fiscal second-quarter results after the close the evening before that beat on revenue and earnings and raised full-year guidance. Product revenue re-accelerated to about 37% growth (roughly $1.49 billion), adjusted earnings of about $0.62 a share topped the roughly $0.45 expected, and management lifted its full-year product-revenue outlook to about $6.07 billion. The beat-and-raise sparked a sympathy surge across software stocks intraday, though much of that broader move faded by the close.

What were the key numbers in Snowflake's fiscal Q2?

Product revenue rose about 37% year over year to roughly $1.49 billion (an acceleration and a second straight quarter of record sequential dollar growth), and total revenue was about $1.55 billion, up ~35%. Adjusted (non-GAAP) earnings were about $0.62 a share versus the roughly $0.45 analysts expected. Non-GAAP operating margin expanded more than 400 basis points to about 15%. Management raised its full-year product-revenue target to about $6.07 billion (from roughly $5.84 billion in May) and guided Q3 product revenue to about $1.59 billion.

Why did other software stocks like Datadog and MongoDB also rise?

Snowflake's beat-and-raise sparked a sympathy surge across enterprise-software names intraday, on the idea that AI is a tailwind rather than a threat — enterprises deploying AI need more data infrastructure, observability and managed databases. Datadog and MongoDB (whose revenue rose ~30% to ~$772 million) rose only modestly. But that broader enthusiasm largely faded through the session: Datadog and MongoDB closed up only about 2.6% and 2.4%, while Snowflake held a ~16.5% gain on its own results — a sign the durable move was company-specific rather than a lasting sector re-rating.

Is Snowflake profitable?

It depends on the measure. Snowflake is profitable on an adjusted (non-GAAP) basis and generates roughly $1.2 billion of annual free cash flow at a gross margin near 67%. But it remains unprofitable on a GAAP basis, with a trailing net loss of about $1.1 billion, largely because of heavy stock-based compensation. The improving non-GAAP operating margin — up more than 400 basis points year over year to about 15% — is a big part of the bull case, but the GAAP losses and stock comp are a key part of the bear case.

Is Snowflake stock expensive after the jump?

By most measures, yes. After a roughly 55% gain over the past year and a 16.5% earnings-day close, Snowflake trades at about 15 times forward sales — a demanding multiple that assumes years of 25%-plus growth. It closed somewhat below the average analyst price target of about $395 (even after a wave of same-day target increases), so the Street still sees modest upside. The bull case rests on durable, AI-driven consumption growth and expanding margins justifying the premium; the bear case is that the price already reflects near-flawless execution, and the fact that the small, fading sympathy lift in peers hints the broader enthusiasm was thin.

What do analysts think of Snowflake stock now?

Coverage is overwhelmingly bullish. The consensus is a Strong Buy — 35 Strong Buy and 10 Buy of 52 analysts, with 7 Holds and no Sells — and the average 12-month target is about $395, in a range from a low near $110 to a high of $525. After the quarter, several firms raised targets, including Scotiabank's Patrick Colville (to $440), Cantor Fitzgerald's Thomas Blakey (to $430), Raymond James's Adam Tindle (to $425) and Deutsche Bank's Brad Zelnick (to $400). Notably, even after those increases the average target sits only about 6% above the post-earnings price.

View all research →
An abstract visualization of a falling stock chart over a search and AI motif in orange-red tones, representing Reddit's crash after a Q3 revenue beat was overshadowed by a Google AI search-traffic warning.
Stock AnalysisOctober 30, 2026 · 12 min read

Reddit (RDDT) Crashes ~30% After a Q3 Beat on a Google AI Search-Traffic Warning

Reddit crashed about 30% to roughly $90.79 on October 30 — a striking reaction, because the quarter itself was strong: revenue of $895 million rose 53% year over year, a clear beat, with net income of $283 million, diluted EPS of $1.40 and adjusted EBITDA of $402 million. The stock cratered on what management said about the future. On the earnings call, CEO Steve Huffman warned that search referrals fell more than a million per week on average in October as Google answers more queries with AI, and that daily active users (around 130 million) could fall a low-double-digit percentage in the fourth quarter if the trend held. Investors also fixed on a 2% year-over-year decline in US daily actives — Reddit's most valuable market, where revenue per user is more than five times the international level — and on fourth-quarter revenue guidance of $1.00–$1.03 billion that came in below expectations; Citizens downgraded the stock before the open. The one bullish counterweight was monetization: revenue per user still jumped 36% globally. The move was company-specific — Reddit's roughly 30% drop was about four times the moves of social peers Snap and Pinterest (each down ~7%), on a day the broad market fell about 2%. After the crash Reddit trades at roughly 14 times forward earnings with about $3 billion of net cash — not expensive for 50%-plus growth, if the growth is durable. The whole debate is whether rising revenue per user can keep outrunning a top of the funnel that AI search is draining.

An abstract visualization of a falling stock chart over an automotive and circuit-grille motif in steel-blue and red tones, representing General Motors' drop after a Q3 beat-and-raise was overshadowed by 2027 cost and EV concerns.
Stock AnalysisOctober 20, 2026 · 10 min read

General Motors (GM) Falls ~8% Despite a Q3 Beat and a $20B Buyback

General Motors fell about 8% to roughly $75.77 on October 20 — a striking reaction, because GM beat on third-quarter earnings, raised its full-year profit outlook and announced a $20 billion buyback. Adjusted earnings of $3.70 a share topped estimates on revenue of about $50 billion, and GM lifted the midpoint of its full-year adjusted-EPS guidance to about $13.25 (from $13.00) and raised its free-cash-flow outlook. The stock fell anyway on what the guidance implied, not the quarter. The full-year outlook implies a softer fourth quarter — only about $2.7 billion of operating profit versus $4.1 billion in the third, as a Silverado/Sierra redesign temporarily cuts truck deliveries by roughly 35,000 units — the raised $13.25 EPS midpoint still landed just below the roughly $13.41 the Street expected, and management flagged about $2 billion of 2026 cost inflation plus a conditional scenario of more in 2027. Two things that look like culprits mostly were not: the 62% drop in EV sales was already known and reflects a distorted 2025 comparison, and tariff costs are now expected near the low end of an existing range. Crucially, GM did not cut its 2027 outlook — it still expects next year to improve if conditions hold. The move was clearly company-specific — Ford fell only about 1%, Stellantis was flat and the S&P 500 rose — so this was a repricing of GM's forward earnings, not an auto-sector sell-off. The valuation captures the tension: GM trades at barely five to six times the forward earnings it guides to, extraordinarily cheap, because the market prices automakers for the downturn, not the peak. A $20 billion buyback into that multiple is powerfully accretive if earnings hold — but whether they hold in 2027 is exactly the question. Analysts keep a Buy consensus and an average target near $104.

An abstract visualization of a rising stock chart over a molecular antibody and DNA-helix motif in cool teal and violet tones, representing Summit Therapeutics' jump on a new ivonescimab kidney-cancer trial.
Stock AnalysisOctober 19, 2026 · 10 min read

Summit Therapeutics (SMMT) Jumps ~6% on a New Ivonescimab Kidney-Cancer Trial

Summit Therapeutics rose about 6% to roughly $15.57 on October 19 after announcing it had opened a global Phase II trial of ivonescimab — its closely watched lead drug — in previously untreated advanced clear cell kidney cancer, with partner Akeso. The key nuance: this is the opening of a mid-stage study, not a data readout, so it is an incremental catalyst that expands the story rather than one that proves it. Summit is effectively a one-drug company: ivonescimab is a PD-1/VEGF bispecific antibody, licensed from China's Akeso, that outperformed Merck's Keytruda in a Chinese lung-cancer trial — nearly doubling progression-free survival and, in updated data, delivering a significant overall-survival benefit (30.8 vs 22.6 months) — though the global trial behind its U.S. filing has yet to formally confirm that survival benefit in Western patients. With no product revenue and a market value above $12 billion, essentially all of Summit's worth is the market's bet on that drug, so a new indication is a fresh call option on the thesis. Two bigger items frame it: AstraZeneca agreed in late September to invest about $2 billion in Summit equity (a ~12% stake), transforming the balance sheet and removing the financing overhang, and the FDA has a November 14, 2026 decision date on ivonescimab in EGFR-mutated lung cancer — a near-term, binary catalyst that matters far more than a trial start. Monday's move was partly company-specific and partly a tailwind: biotech broadly rallied, with the sector ETF up about 2.5%, but Summit outperformed. The risks are a binary valuation on one molecule, an unconfirmed Western survival benefit, and a stock down roughly 47% from its high. Analysts carry a Buy consensus and an average target near $30, inside a wide range from about $12 to the mid-$40s.